glp 1 agonist approved for weight loss Is GLP-1 Safe Loss? Peptides, Benefits & Risks GLP-1: Genetic Variants Related to

While newly approved pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show efficacy, their clinical utility remains constrained by dose-dependent gastrointestinal complications, underscoring the urgent need for safer alternatives

The GLP-1 drugs market size is predicted to grow from USD 58.05 billion in 2026 to USD 132.79 billion by 2035, driven by a CAGR of 9.63%.

Understanding these conflicts helps ensure safe, successful treatment with semaglutide or tirzepatide

Conclusion: This review synthesizes current evidence on the safety and effectiveness of GLP-1RAs in weight management and potential cardiovascular protection

Given the potential for increased INR variability, clinicians may consider increasing INR monitoring frequency following GLP-1 RA initiation.

With an FY18 Multiple Sclerosis Research Program Investigator-Initiated Research Award, Dr